Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know

Moderna (MRNA) closed the most recent trading day at $54.26, moving +2.69% from the previous trading session.

Moderna (MRNA) Stock Declines While Market Improves: Some Information for Investors

In the latest trading session, Moderna (MRNA) closed at $51.3, marking a -1.54% move from the previous day.

Bank of America flags international opportunities as key growth driver for Moderna

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to highlight progress in international COVID-19 vaccine markets when it reports first quarter 2026 results,...

Moderna eyes international markets as growth driver, says Bank of America

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to highlight progress in international COVID-19 vaccine markets when it reports first quarter 2026 results,...

Moderna Aktienanalyse: Zwischen Gegenwind und Comeback-Fantasie - Warum RBC Capital vorsichtig optimistisch bleibt

Bad Marienberg (www.aktiencheck.de)???? Moderna im Realitätscheck: Vom Pandemie-Gewinner zur strategischen WetteDie Aktie von Moderna Inc. (ISIN: US60770K1079, WKN: A2N9D9, Ticker-Symbol: 0QF, NASDAQ-Symbol: MRNA) befindet sich in einer entscheidenden Phase. Nach dem historischen Boom während der Pandemie steht das Unternehmen nun vor der Herausforderung, sich als langfristiger Biotech-Player neu zu positionieren. [mehr]

Moderna: Speculative Buy For Aggressive Investors Betting On mRNAs Future

Modernas mRNA pipeline—cancer vaccines, Norovirus, and a European comeback—could fuel triple-digit EPS growth by 2030. Read why MRNA stock is a speculative buy.

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and patented drugs.

Moderna (MRNA) Stock Dips While Market Gains: Key Facts

In the closing of the recent trading day, Moderna (MRNA) stood at $49.2, denoting a -1.66% move from the preceding trading day.

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and patented drugs. This potential move would target pharmaceutical companies that have not negotiated deals to lower drug prices in the United Stat…

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know

Moderna (MRNA) concluded the recent trading session at $49.56, signifying a -7.49% move from its prior days close.

These Top Stocks Have a Big China Problem to Solve

Modern problems require modern solutions, and thats what Detroit automakers are currently figuring out in China.

ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential?

IBRX and MRNA hinge on single-drug success, but pipeline depth, growth plans and risks set them apart in the race for biotech upside.

Moderna Stock is Soaring. Is It Too Late to Buy?

Modernas full pipeline may fuel long-term growth.

Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights

In the latest trading session, Moderna (MRNA) closed at $51.38, marking a -1.89% move from the previous day.

Pfizer vs Moderna: Which Pharma Stock Has More Upside?

They arent just "pandemic stocks."

OTC Markets Hosts Virtual Investor Presentation with Dr. Seth Lederman, Co-Founder, CEO, and Chairman of Tonix Pharmaceuticals, and David Bautz, PhD, Senior Analyst at Zacks SCR

NASDAQ: TNXPJohn Viglotti: Hello, and welcome to the Life Sciences Investor Forum. On behalf of OTC Markets and our co-host, Zacks Small Cap Research, were very pleased youve joined us. Our next presentation is from Tonix Pharmaceuticals. Their session will be moderated by David Bautz, Senior Equity Analyst with Zacks Small Cap Research. Please note you can submit questions for the presenter, and you can view our companys availability for one-on-one meetings by clicking book a meeting. At t...

Moderna (MRNA) Declines More Than Market: Some Information for Investors

In the most recent trading session, Moderna (MRNA) closed at $52.56, indicating a -1.55% shift from the previous trading day.

Stocks making the biggest moves midday: Coinbase, CoreWeave, KKR, Moderna, Brown-Forman & more

Here are some of the stocks making the biggest moves in midday trading.

Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang

Moderna shares rose 10% in premarket trading on Wednesday after the company settled a long-running legal battle over the technology that made its COVID-19 vaccine possible, removing an overhang and allowing it to ?focus on its pipeline.

Stocks making the biggest moves premarket: Moderna, Ross Stores, Box, Gitlab and more

These are the stocks posting the largest moves in premarket trading.

Moderna to pay up to $2.25B to settle COVID vaccine patent matter

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) stock added almost 9% after it was announced that the drugmaker has agreed to pay up to $2.25 billion to settle a...

Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna

BASEL, Switzerland and LONDON and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant, and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, have entered into a $2.25 billion global settlement with Moderna, Inc. to resolve...

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

BASEL, Switzerland and VANCOUVER, British Columbia, March 03, 2026 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant Sciences Ltd. (Nasdaq: ROIV), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that they have entered into a $2.25 billion global settlement with Moder...

Pivotal-Point Nachverfolgung Moderna (MRNA): Abkehr vom COVID-Fokus nach Durchbruch bei personalisierter Krebs-Immuntherapie!

Moderna ist ein Pionier im Bereich der mRNA-Technologie und wurde durch den Erfolg seines COVID-19-Vakzins weltweit bekannt. Am 18. Februar lösten positive Phase-3-Daten für eine personalisierte Krebsimpfung...

Modernas Ups and Downs: Heres What You Need to Know Before Investing.

The stock, after a few tough years, soared in the double-digits in January.

Moderna Aktie: Paukenschlag - aber kein Grund zur Euphorie!

Charlotte (www.aktiencheck.de) - Moderna-Aktienanalyse der Bank of America (BofA):Der BofA-Analyst Alex Stranahan habe das Kursziel für die Aktie von Moderna Inc. (ISIN: US60770K1079, WKN: A2N9D9, Ticker-Symbol: 0QF, NASDAQ-Symbol: MRNA) von 27 auf 31 USD angehoben und das "underperform"-Rating beibehalten. [mehr]

Netflix, Klarna, Shopify, Palo Alto, Moderna: What brokers said this week

BioNTech verklagt Moderna – die Details

BioNTech ist im Patentstreit gegen Moderna vor Gericht gezogen. Das Mainzer Biotech-Unternehmen hat beim Bundesgericht im US-Bundesstaat Delaware Klage eingereicht und wirft dem US-Konzern vor, mit seinem neuen Covid-19-Impfstoff „mNEXSPIKE“ Schutzre...